XML 14 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Licensing revenue $ 125,000 $ 125,000 $ 375,000 $ 375,000
Operating expenses:        
Research and development 2,491,696 3,674,239 8,534,606 9,999,972
General and administrative 1,792,904 1,838,287 5,532,946 6,192,835
Total operating expenses 4,284,600 5,512,526 14,067,552 16,192,807
Loss from operations (4,159,600) (5,387,526) (13,692,552) (15,817,807)
Other (expense) income:        
(Loss) gain from change in valuation of earn-out milestone liability (1,099,721) 85,882 (1,397,291) 3,088,821
Impairment of in-process research and development (2,370,257) (2,370,257)
Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments (400,000)
Investment income 10,114 174,439 119,383 432,832
Interest expense (450,732) (349,602) (1,130,699) (1,049,797)
Other (expense) income (1,400) 7 (2,823)
Total other (expense) income, net (3,911,996) (89,281) (4,778,857) 2,069,033
Net loss $ (8,071,596) $ (5,476,807) $ (18,471,409) $ (13,748,774)
Net loss per common share - Basic and diluted $ (0.24) $ (0.25) $ (0.62) $ (0.67)
Weighted average shares outstanding - Basic and diluted 34,112,254 21,662,824 29,934,764 20,524,799